2011/869/EU: Commission Decision of 20 December 2011 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (notified under document C(2011) 9398)  Text with EEA relevance
Date: 2011-12-20
Institutions: European Commission
Subjects: disease of the nervous system, marketing standard, medical device, medical diagnosis, technical specification








L_2011341EN.01006301.xml










22.12.2011   


EN


Official Journal of the European Union


L 341/63








            COMMISSION DECISION
         
of 20 December 2011
         
amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices
(notified under document C(2011) 9398)
(Text with EEA relevance)
(2011/869/EU)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices (1), and in particular the second subparagraph of Article 5(3) thereof,

Whereas:







(1)


The common technical specifications for in vitro diagnostic medical devices are laid down in Commission Decision 2002/364/EC (2).












(2)


In the interest of public health it is appropriate, where possible, to draw up common technical specifications for the devices listed in List A of Annex II to Directive 98/79/EC.












(3)


Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening, diagnosis and confirmation have been added to List A of Annex II to Directive 98/79/EC by Commission Directive 2011/100/EU (3).












(4)


Taking into account the state of the art and the current scientific knowledge on Variant Creutzfeldt-Jakob disease, common technical specifications can be drawn up for vCJD blood screening assays.












(5)


The measures provided for in this Decision are in accordance with the opinion of the committee set up by Article 6(2) of Council Directive 90/385/EEC (4) and referred to in Article 7(1) of Directive 98/79/EC,





HAS ADOPTED THIS DECISION:



Article 1
The Annex to Decision 2002/364/EC is amended in accordance with the Annex to this Decision.


Article 2
This Decision shall apply from 1st of July 2012.
However, Member States shall allow manufacturers to apply the requirements set out in the Annex before the date set out in the first paragraph of this Article.


Article 3
This Decision is addressed to the Member States.




Done at Brussels, 20 December 2011.


For the Commission

John DALLI
            

Member of the Commission






(1)  
            OJ L 331, 7.12.1998, p. 1.

(2)  
            OJ L 131, 16.5.2002, p. 17.

(3)  See page 50 of this Official Journal.

(4)  
            OJ L 189, 20.7.1990, p. 17.




ANNEX

1.   
The following section is added at the end of Section 3 of the Annex to Decision 2002/364/EC:
‘3.7.   CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening

CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening are set out in Table 11’
                  


2.   
The following table is added at the end of the Annex to Decision 2002/364/EC:
‘Table 11


Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening









 


Material


Number of specimens


Acceptance Criteria




Analytical sensitivity


vCJD brain spikes in human plasma (WHO reference number NHBY0/0003)


24 replicates of each of three dilutions of the material WHO number NHBY0/0003
(1×104, 1×105, 1×106)


23 of the 24 replicates detected at
1×104





vCJD spleen spikes in human plasma (10 % spleen homogenate — NIBSC reference number NHSY0/0009)


24 replicates of each of three dilutions of the material NIBSC number NHSY0/0009
(1×10, 1×102, 1×103)


23 of the 24 replicates detected at
1×10




Diagnostic sensitivity








A)


Specimen from appropriate animal models






As many specimen as reasonably possible and available, and at least 10 specimens


90  %










B)


Specimen from humans with known clinical vCJD






As many specimen as reasonably possible and available, and at least 10 specimens


90  %




Only in case where 10 specimens are not available:






—


the number of specimens tested shall be comprised between 6 and 9










—


all available specimens shall be tested






no more than one false negative result




Analytical specificity


Potentially cross-reacting blood-specimens


100 


 




Diagnostic specificity


Normal human plasma samples from area of low BSE exposure


5 000 


At least 99,5 %’